A bnormalities of various transcriptional and posttranscriptional regulators have been shown to play important roles in human vascular disease. Manipulation of these target genes remains a major focus of ongoing research, with the goal of developing novel therapeutic strategies to combat ischemic cardiovascular disease. 1 Recently, a novel class of small noncoding RNAs, called microRNAs (miRNA), have been identified as important transcriptional and posttranscriptional inhibitors of gene expression that regulate the translational output of target messenger RNAs. 2, 3 Selective miRNAs have been identified in vascular endothelial cells, where they play key roles in regulating the angiogenic process. [4] [5] [6] The ability to modulate key miRNAs involved in angiogenesis may lead to therapeutic applications for vascular diseases characterized by impaired angiogenesis. [7] [8] [9] Thus, techniques to deliver miRNAbased therapies, 8 targeted specifically to the vascular endothelium and using a noninvasive approach, would be an important step toward the development of a safe and effective strategy for miRNA delivery. November 2015 angiogenic response. 12 The noninvasive nature of UTMD facilitates multigene delivery for therapeutic angiogenesis, which when given in a temporally separated fashion leads to more sustained and functional neovascularization. 13 The advantages of (1) targeted vascular transfection, (2) minimal delivery to remote regions, and (3) noninvasive methodology makes UTMD uniquely suited to proangiogenic miRNA delivery.
One specific miRNA, miR-126-3p, has unique properties that make it an attractive therapeutic target. 14, 15 It is one of the only endothelial cell-restricted miRNA and has been shown to regulate vascular integrity and developmental angiogenesis. Deletion of the endothelial cell-specific miR-126-3p impairs maintenance of vascular integrity during embryogenesis and reduces angiogenesis after myocardial infarction in mice. 15 The proangiogenic effect of miR-126-3p has been attributed to the repression of sprouty-related protein-1 (SPRED-1) and phosphatidylinositol-3-kinase regulatory subunit 2 (PIK3R2), 2 negative regulators of vascular endothelial growth factor (VEGF) signaling, leading to enhanced VEGF action. 14, 15 More recently, the sister strand of miR-126-3p, miR-126-5p, has also been shown to have a biological effect, promoting endothelial proliferation and limiting atherosclerosis. 16, 17 The aims of our present study was to (1) develop and optimize UTMD techniques for miRNA therapeutics and (2) to test UTMD of miR-126-3p for therapeutic angiogenesis in the setting of chronic hindlimb ischemia. Our results demonstrate that miR-126-3p can be bound to cationic microbubbles, prolonging miRNA circulatory time in vivo after intravenous injection. UTMD of miR-126-3p results in knockdown of SPRED-1 and PIK3R2 along with positive modulation of angiopoietin-1 (Ang)-1 signaling, without effects on miR-126-5p. Finally, UTMD of miR-126-3p results in improved perfusion, increased vessel density and arteriolar to capillary ratio, and enhanced pericyte coverage in chronic hindlimb ischemia. This study provides strong evidence supporting UTMD as an effective noninvasive technique for miRNA delivery for therapeutic angiogenesis.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

miRNA-126-3p Transfection and Knockdown of SPRED1 and PIK3R2 In Vitro
We first tested the effects of miR-126-3p transfection (siPORT NeoFX) in human umbilical vein endothelial cells (HUVECs). MiR-126-3p levels by polymerase chain reaction in HUVECs showed peak expression at day 2 after transfection and was unchanged after transfection with scrambled miRNA ( Figure 1A ). MiR-126-3p-transfected HUVECs showed repression of SPRED-1 and PIK3R2, negative regulators of VEGF signaling, peaking 24 hours after transfection and persisting out to day 3 ( Figure 1B ). In comparison, scramble miRNA-transfected HUVECs showed no significant repression of either SPRED-1 or PIK3R2 ( Figure 1B) . When transfected with fluorescent miRNA, transfection in HUVECs was localized to cytoplasm and the nucleus ( Figure 1C ). This data suggest that exogenous miR-126-3p enters the cell (nucleus) and has strand-specific effects and is not a secondary effect.
In Vitro Stimulation With Ang-1 in miR-126-3p-Transfected HUVECs (Phosphorylated Tie2 Measurement)
The transfection of HUVECs with miR-126-3p had no effect on the levels of phosphorylated Tie2. However, under stimulation with Ang-1, miR-126-3p transection led to increased levels of phosphorylated Tie2 protein (P<0.001 versus all other groups; Figure 1D ). The increase in phosphorylated Tie2 was because of knockdown of PIK3R2 and not because of inhibition of SPRED1 ( Figure 1E and 1F). This demonstrates the positive modulation of Ang-1 effect by miR-126-3p transfection and knockdown of PIK3R2, leading to enhanced phosphorylation of the Tie2 receptor.
In Vitro Migration and Tubule Formation
In vitro endothelial cell function in response to miR-126-3p transfection was assessed by Matrigel Tubule formation and standard Boyden Migration assays in our laboratory. 18 Functional analysis of miR-126-3p-transfected HUVECs showed greater angiogenic potential by enhanced matrigel tubule formation and migration studies in transfected cells when compared with control and scrambled miRNAtransfected HUVECs, with increased nodes and tubes (Figure 2A -2D). Next we performed additional in vitro matrigel angiogenesis experiments with specific inhibitors of VEGFR2 and Tie2 to determine the relative contributions of VEGF and Ang-1 to miR-126-3p-mediated neovascularization ( Figure 2E-2F ). This showed that the proangiogenic effect of miR-126-3p was suppressed by blockade of both VEGFR2 and Tie2, with a greater suppression by blockade of VEGFR2. These data provide in vitro evidence of the proangiogenic potential of miR-126-3p.
miR-126-3p Microbubble Conjugation and In Vivo Circulation
Cationic microbubbles were charge-coupled to a varying range of miR-126-3p under different conditions to optimize for a range of miR-microbubble binding conditions. After miR-126-3p and microbubble conjugation, binding of miR-126-3p to 1×10 9 cationic microbubbles saturated at ≈60 000 miR-126-3p molecules per microbubble with the addition of 2.5 μg of miR-126-3p ( Figure IA 
miRNA-126-3p Transfection by UTMD In Vivo in Normal Hindlimb
UTMD of miR-126-3p produced targeted transfection in nonischemic (normal) Fischer 344 rat hindlimb skeletal muscle, peaking early at 3 hours after delivery and lasting for 3 days ( Figure 3A ), and resulted in inhibition of SPRED-1 and PIK3R2 by polymerase chain reaction ( Figure 3B ), with no changes detected after UTMD of scrambled miRNA ( Figure II in the online-only Data Supplement). Knockdown of SPRED1 and PIK3R2 mRNA levels was highest at 24 hours after delivery and persisted for 3 days in UTMD miR-126-3p-delivered groups ( Figure 3B ). Representative Western blots demonstrating reduced SPRED-1 and PIK3R2 at days 1 and 3 are shown in Figure 3C . There was minimal to no uptake in remote 
miRNA-126-3p Levels in Ischemic Hindlimb After UTMD
First, we examined endogenous expression of miR-126-3p and miR-126-5p in our ischemic hindlimb model ( Figure 4A and 4B). There was a similar trend (P>0.05) of increasing expression of both miR-126-3p and miR-126-5p after ischemia, with miR-126-3p levels being ≈2× that of miR-126-5p at all time points, both peaking at 2 weeks after left femoral artery ligation and stripping. Next, we performed UTMD (1×10 9 cationic microbubbles charge-coupled with 2.5 μg of miR-126-3p or scrambled miRNA [2.5 μg], ultrasound settings 1.3 MHz, transmit power of 0.9 W [120 V, 9 mA, peak negative acoustic pressure −2100 kPa at a pulsing interval of 5 s]) [11] [12] [13] in Fischer 344 rats at 2 weeks after left femoral artery ligation and stripping, with a subset of ischemic animals receiving 3 rounds of UTMD of miR-126-3p (day 14, 16, and 18 after ligation/stripping). In the setting of chronic ischemia, miR-126-3p-delivered animals showed higher miR-126-3p levels in the delivered hindlimb, indicating effective transfection of miR-126-3p at the target site (P<0.05 versus control and scramble) at day 15 (24 hours after delivery) and remained elevated for 3 days (P<0.05 versus control and scramble at day17; Figure 4C ). By day 28 (14 days after delivery), miR-126-3p levels were back to basal levels, showing no difference to control and scrambled-delivered groups ( Figure 4C ).
Localization of miRNA Transfection: In Situ Hybridization and Fluorescent Microscopy
In situ hybridization showed robust miR-126-3p expression in miR-126-3p-delivered animals both at 24 and 72 hours after delivery, with both vascular and peri-vascular transfection ( Figure 4D ). There was detectable signal in both control and scrambled ischemic muscles consistent with endogenous miR-126 expression, but greater signal was seen (reddish-brown staining, black arrows) after UTMD of miR-126-3p within ischemic muscle. To further assess localization of miR transfection, we performed UTMD of fluorescent miRNA to ischemic hindlimb muscle. At day 1 post-UTMD of fluorescent miRNA, we found red fluorescent miRNA in ischemic muscle co-localized to endothelial cells, confirming targeted vascular transfection ( Figure 4E ).
miRNA-126-3p Induced Target Knockdown In Vivo in Ischemic Hindlimbs
UTMD of miR-126-3p to ischemic hindlimb muscle decreased protein expression of PIK3R2 and SPRED1 by Western blot. The greatest knockdown of both PIK3R2 and SPRED1 was at 24 hours and day 3 after delivery, with the knockdown effect of miR-126 diminished by day 28 (day 14 after UTMD). Protein expression levels of PIK3R2 and SPRED1 were no different across scrambled and nontreated control groups ( Figure 5A and 5B). Triple delivery of miR-126-3p via UTMD to ischemic muscle showed knockdown of SPRED1 and PIK3R2 protein expression assessed by Western blotting, with robust knockdown of PIK3R2 at an early time point of day 19 (1 day after the final/3rd UTMD) that persisted until day 28 ( Figure 5C ). When compared with single miR-126-3p delivery, triple miR-126-3p UTMD delivery showed even greater knockdown of PIK3R2 and SPRED1 at the protein and mRNA level, with more prolonged knockdown of PIK3R2 at day 28 compared with single delivery (Figure 5D-5F) . Given recent data on the biological effects of the sister strand of miR-126-3p, we quantified miR-126-5p expression in all 3 treatment groups. We did not observe any significant changes in miR-126-5p levels at day 15 and day 28 after ligation (day 1 and day 14 after UMTD) across all 3 groups ( Figure IVA in the online-only Data Supplement). Specifically, there was no downregulation of miR-126-5p after UTMD of miR-126-3p. Given the effect of miR-126-5p in suppressing Notch1 inhibitor delta-like 1 homolog, 16 we examined delta-like 1 homolog expression in all treatment As can be seen from the representative Western blots and quantitative data presented in the graphs, target knockdown peaked at day 15 and remained significantly downregulated out to day 17 (PIK3R2: *P<0.01 vs control and scramble; SPRED1: †P<0.05 vs control and scramble; N=7-10 per time point for each group). Data expressed as mean±SEM. C, Triple delivery of miR-126-3p via UTMD to ischemic muscle showed knockdown of SPRED1 and PIK3R2 protein expression assessed by Western blotting. Triple delivery of miR-126-3p via UTMD resulted in a greater knockdown at early time point of day 19 (PIK3R2, *P<0.01 vs control; SPRED1, *P<0.01 vs control, N=5) and a more prolonged knockdown of PIK3R2, which persisted until day 28; †P<0.05 vs. control). D, Compared with single miR-126-3p delivery, the triple delivery (miR-126-3p [×3]) showed greater knockdown of PIK3R2 and SPRED1 at the protein level. With triple delivery, there is a more prolonged knockdown of PIK3R2 at day 28 compared with single delivery. Data expressed as mean±SEM. Triple delivery of miR-126-3p via UTMD to ischemic hindlimb muscle shows significant inhibitory effect on PIK3R2 (E) and SPRED1 (F) at the mRNA level at day 28. *P<0.05 vs control and miR-126-3p (×1). N=8 to 10 per group.
groups. In keeping with a lack of change of miR-126-5p, we did not see any change in delta-like 1 homolog expression with UTMD of miR-126-3p ( Figure IVB in the online-only Data Supplement). In contrast to studies showing delivery of miR-126-3p by apoptotic bodies can induce CXCL12, 19 we did not find any changes in CXCL12 expression after UTMD of miR-126-3p ( Figure IVC in the online-only Data Supplement).
Therapeutic Angiogenesis by UTMD of miR-126-3p in Chronic Ischemia
Contrast-enhanced ultrasound was used to assess tissue perfusion over time in all treatment groups. [11] [12] [13] Representative parametric contrast-enhanced ultrasound perfusion images of the ischemic hindlimb (transverse/cross-sectional images of the ischemic gastrocnemius/soleus muscle) at day 28 in all animal groups are shown in Figure 6A . UTMD of miR-126-3p to chronic ischemic hindlimb muscle resulted in significant improvement in microvascular perfusion ( Figure 6B ). At day 28 (2 weeks after treatment), only animals receiving UTMD miR-126-3p treatment showed improvement in normalized perfusion to 0.79±0.03 (P<0.05 versus perfusion at day 14, pre-UTMD). A subset of animals underwent repeated (3×) UTMD of miR-126 (day 14, day 16, and day 18), where the resulting angiogenic response was even greater, with normalized microvascular perfusion at day 28 increasing even further to 0.88±0.02 ( Figure 6C ).
Fluorescent Microangiography
Microvascular density and neovessel characterization was assessed using fluorescent microangiography, a method of postmortem vascular casting. [11] [12] [13] Fluorescent microangiography ( Figure 6D ) of hindlimb muscle showed increased vessel density in miR-126-3p-treated animals compared with control and scramble-treated groups. Through analysis of the vasculature in the ischemic hindlimb of animals, both the total vessel length ( Figure 6E ) and vascular density ( Figure 6F ) of the miR-126-3p-treated group was significantly greater compared with control and scramble treatment groups. By branch Figure 6 . Microvascular perfusion and vascular density of the ischemic hindlimb is improved after ultrasound targeted microbubble destruction (UTMD) of miR-126-3p. A, Representative parametric contrast-enhanced ultrasound (CEU) perfusion images of microvascular blood flow to ischemic hindlimb in all treatment groups at day 28 after ligation (day 14 after UTMD). Red and yellow represent areas of high microvascular blood flow. B, CEU perfusion data for ischemic hindlimb muscle at day 14 (before UTMD of miR-126-3p) and day 28 (14 days after UTMD of microRNA [miRNA]) across treatment groups (*P<0.05 vs perfusion at day 14; control N=23, scramble N=26, miR-126-3p N=31). C, After repeated (3×) UTMD of miR-126-3p (N=10), CEU perfusion to ischemic muscle at day 28 was significantly greater than single UTMD (*P<0.05 vs single miR-126-3p delivery). D, Representative fluorescent microangiographic images of the vasculature in the ischemic leg of animals from all groups. Scale bar=100 μm. Quantitative fluorescent microangiography (FMA) of miR-126-3p-treated muscle showed increased total vessel length (E; μm), vascular density (F; μm³), and arteriolar/capillary ratio (G). *P<0.01 vs control and scramble for vessel length and vascular density; *P<0.05 vs control and scramble for arteriolar/capillary ratio (N=8 per group). Data expressed as mean±SEM. H, Representative immunostaining images of ischemic muscle from each treatment group at day 28 after ligation demonstrating enhanced pericyte coverage in the miR-126-3p-treated group. Left panels show capillaries with endothelial staining (Von Willebrand factor [vWF]; red), pericyte staining (Desmin; green), and merge with nuclear counterstain (DAPI; blue). The right panels show arteriolar staining. There is greater pericyte (green) coverage in miR-126-3p-treated animals. Scale bar =100 μm. I, %Desmin positive cells, P<0.05 vs control and scramble, N=10 per group. Scale bar=100 μm. order analysis, 13 miR-126-3p delivery by UTMD resulted in a higher arteriolar/capillary ratio compared with scramble and control groups at day 28 ( Figure 6G ).
Immunohistochemistry and Tie2 Expression
Immunostaining was performed on hindlimb skeletal muscle, using antibodies against von Willebrand Factor (endothelial cells) and Desmin (pericytes). After UTMD of miR-126-3p, there was a significant increase in desmin-positive arterioles and capillaries compared with scrambled-treated and control ischemic muscle ( Figure 6H and 6I) . Desmin is a marker of pericytes, with increased pericyte coverage suggesting greater vessel maturation and stabilization in miR-126-treated muscle compared with scrambled miRNA-treated and control ischemic muscle. Improved pericyte coverage is a marker of enhanced Ang-1 effect 13,20 mediated by UTMD of miR-126-3p. In keeping with an enhanced Ang-1 effect and our in vitro data, UTMD of miR-126-3p to ischemic hindlimb muscle showed significant upregulation of phosphorylated Tie2 and Tie2 levels at the protein level at day 28 after ligation ( Figure V in the online-only Data Supplement).
Discussion
Current evidence indicates that miRNAs are important regulators in many cardiovascular diseases and, coupled with their ability to specifically target key cellular pathways, makes the possibility of exploiting miRNAs to develop novel therapeutic strategies extremely attractive. Several miRNAs, termed angiomiRs, have been identified that regulate vascular development, angiogenesis, and endothelial cell function. 6, 21 The identification of these angiomiRs as key regulators of angiogenesis has opened a new avenue for cardiovascular therapeutics for ischemic cardiovascular diseases. Although many techniques exist, the optimal delivery method for proangiogenic miRNA therapies remains to be determined. Our present study demonstrates that ultrasound-mediated miR-126-3p delivery results in targeted vascular miR-126-3p transfection, increased vascular density, and improved microvascular perfusion with minimal to no uptake in remote organs, and it as such is a promising noninvasive technique for proangiogenic miRNA therapeutics.
There are several important advantages to miRNAs as therapeutic agents. 7, 8, 22 Their small size and conserved sequence across species make them more amenable to translation to product development for human application. In addition, the ability of one miRNA to target multiple mRNAs that function in the same or closely related intracellular pathway or signaling cascade is an advantage over targeting one specific gene. A major challenge in the development of miRNA-based therapeutics concerns the potential for systemic delivery into targeted sites, such as a specific organ, like the heart, or cell type within an organ, like the vascular endothelium. Although native circulating miRNAs are stable in plasma because of protection by exosomes, microvesicles, or lipoprotein complexes, 23, 24 exogenously administered synthetic miRNAs are subject to RNase-dependent degradation by endogenous ribonucleases. 24 To overcome this limitation, chemical modifications have been performed to stabilize them in vivo and increase binding efficacy and cellular uptake. For example, conjugation of miR 122 antagomiRs to cholesterol can facilitate cellular uptake and biological action within the liver in vivo, 25 leading to reduced plasma cholesterol levels. Similarly, chemical modifications to anti-miR-33 oligonucleotides increase metabolic stability and tissue half-life, leading to a reduction in atherosclerotic plaque burden in LDL receptor knockout mice. 26 Alternatively, miRNA mimics (synthetic RNA duplexes in which one strand is identical to the miRNA sequence, designed to mimic the function of the endogenous miRNA) may lead to downregulation of target genes. 27, 28 We showed that conjugation of miR-126 to cationic lipid microbubbles (≈60 000 miRNA molecules per microbubble), similar to binding to lipoproteins or microvesicles, prolongs their circulatory time in vivo. Although unbound miRNA was rapidly cleared, microbubble conjugation allowed the miRNA to persist in the systemic circulation where they can undergo sitetargeted transfection by focused externally applied ultrasound.
Several other challenges remain for the successful development of miRNA therapeutics, including (1) lack of tissue specificity, (2) lack of optimal delivery methods, (3) risk of systemic or off-target effects, and (4) poor tissue/organ uptake. Although intravenous administration of antimiRs and miRNA mimics have been the primary method of systemic delivery to date, uptake is preferentially targeted to the liver, spleen, and kidney. [29] [30] [31] Thus, efficient and targeted delivery strategies for miRNA are needed, with several currently under investigation, including (1) conjugation to a targeting molecule, such as peptides or antibodies, to promote homing of the antimiR/ miRNA mimic to the target tissue, (2) encapsulation strategies (eg, liposome-based methods) to enhance tissue uptake, and (3) direct delivery techniques, such as catheter-based intracoronary injections. A noninvasive method of miRNA delivery that results in site-targeted transfection, with minimal systemic/off-target effects, would be an important advance to the field of miRNA therapeutics.
UTMD is a noninvasive method of gene delivery that has been studied for viral vector, 32 plasmid, 11, 33 and siRNA delivery. 34 Although other studies have used high-power ultrasound and DNA-bearing carrier microbubbles to deliver plasmid vectors encoding miRNA to the kidney 35 and liver, 36 our study is one of the first to investigate UTMD of miRNA and the first application for cardiovascular therapeutics, specifically aimed at therapeutic angiogenesis in chronic hindlimb ischemia. In addition, we closely detailed the in vivo spatial and temporal aspects of UTMD for miRNA delivery, including localization, timing of transfection, and target knockdown, as well as the benefits of multiple deliveries to improve therapeutic effect. Similar to plasmid delivery, UTMD results in targeted transfection of miR-126 to the vascular endothelium, 11, 12 as shown by in situ hybridization and fluorescent microscopy, and may be a key advantage of UTMD over other miRNA delivery techniques for therapeutic angiogenesis. Transfection occurs rapidly within 3 hours and is transient, lasting 3 days, with target knockdown also occurring rapidly within 24 hours after UTMD, which may be beneficial for miRNA therapies for acute processes, such as acute myocardial ischemiareperfusion injury. Target knockdown was transient and lasted out to day 3, and so for treatment of chronic ischemia, we used repeated deliveries (3 UTMD deliveries every 2 days) to prolong the therapeutic effect, finding multiple deliveries to produce a more sustained target knockdown, and a greater angiogenic response compared with single delivery. Use of miRNA mimics or plasmid vectors encoding miR-126 for UTMD may also prolong transfection and target knockdown, further increasing therapeutic effect, and is worthy of future studies. Importantly, remote uptake was minimal after UTMD of miR-126, with no significant target knockdown in the liver or spleen. Thus, the advantages of (1) targeted vascular transfection, (2) minimal delivery to remote regions, (3) noninvasive delivery method that can be easily repeated make the technique of UTMD uniquely suited to endothelial cellspecific proangiogenic miRNA delivery.
Several studies have investigated therapeutic aspects of miR-126-3p. Zernecke et al demonstrated that delivery of miR-126-3p in endothelial cell apoptotic bodies resulted in plaque stabilization in mouse models of atherosclerosis via increased production of CXCL12. 19 We did not find any changes in CXCL12 with UTMD of miR-126-3p in our study, which may reflect differences in disease model and mode of delivery. Similarly, Jansen et al showed that endothelial microparticles released from apoptotic endothelial cells promote vascular re-endothelialization by transfer of miR-126-3p into recipient endothelial cells, an effect that is blunted in the presence of hyperglycemia. 37 Although miR-126-3p is the dominant strand and the subject of most studies of miR-126, there is increasing interest in the sister strand, miR-126-5p. Schober et al 16 demonstrated that miR-126-5p suppresses Notch1 inhibitor delta-like 1 homolog, maintaining the regenerative capacity of endothelial cells and limiting atherosclerosis. Given the single miR-126-3p strand could theoretically act as an antisense RNA for miR-126-5p, we quantified miR-126-5p expression in vivo in all 3 treatment groups. We found no significant change in miR-126-5p expression either early (1 day) or late (14 days) after UTMD of miR-126-3p. This suggests that the increased angiogenesis observed was mediated only via exogenous miR-126-3p and that miR-126-3p delivery did not lead to suppression of endogenous miR-126-5p.
Our present study showed that miR-126-3p increased tubule formation and migratory capacity of endothelial cells in vitro and that UTMD of miR-126-3p in the setting of chronic hindlimb ischemia in vivo resulted in increased microvascular perfusion and vascular density, with knockdown of known targets SPRED1 and PIK3R2, 14, 15 both negative regulators of VEGF signaling. Interestingly, although miR-126-3p transfection and target knockdown was relatively short-lived, the observed proangiogenic effect persisted for 2 weeks after delivery. Analysis of the neovasculature revealed increased arteriolar/capillary ratio and improved pericyte coverage, suggesting enhanced vessel maturation. This data coupled with our in vitro data showing miR-126-3p-mediated downregulation of PIK3R2 accounts for the increased Tie-2 phosphorylation under the stimulation of Ang-1 in endothelial cells is in keeping with the findings of Sessa et al who showed that miR-126-induced suppression of PIK3R2 also promotes the action of Ang-1 on neovessel stabilization and maturation. 38 Thus, by simultaneously targeting both the VEGF pathway to stimulate early angiogenesis and Ang-1 signaling to promote vessel stabilization, miR-126 therapy results in a more robust angiogenic response, consistent with observations seen with studies of combination VEGF and Ang-1 gene delivery. 13, 39 
Conclusions
We conclude that ultrasound-mediated gene delivery of miR-126-3p-bearing carrier microbubbles to chronically ischemic skeletal muscle results in improved tissue perfusion, vascular density, arteriolar formation, and neovessel maturation, with no significant off-target effects in remote organs. With advantages of targeted vascular transfection and ease of repeated deliveries, UTMD is a promising noninvasive technique for miRNA delivery for therapeutic angiogenesis.
